Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy
DOI:
https://doi.org/10.31288/oftalmolzh20223036Keywords:
proliferative diabetic retinopathy, intravitreal aflibercept, vitrectomyAbstract
Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR).
Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy.
Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy.
Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02).
Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.
References
1.Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012; 60(5): 428-31. https://doi.org/10.4103/0301-4738.100542
2.Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology. 1983; 90(5): 522-30. https://doi.org/10.1016/S0161-6420(83)34540-1
3.Novak MA, Rice TA, Michels RG. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984 Dec;91(12):1485-9. https://doi.org/10.1016/S0161-6420(84)34099-4
4.Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology. 1986 Jan;93(1):39-44. https://doi.org/10.1016/S0161-6420(86)33791-6
5.Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989 Oct;96(10):1495-500. https://doi.org/10.1016/S0161-6420(89)32700-X
6.Neely KA, Scroggs MW, McCuen BW II. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes. Am J Ophthalmol. 1998 Jul;126(1):82-90. https://doi.org/10.1016/S0002-9394(98)00066-X
7.Yeh PT, Yang CM, Yang CH. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study. Ophthalmology. 2005 Dec;112(12):2095-102. https://doi.org/10.1016/j.ophtha.2005.07.010
8.Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007 Apr;114(4):710-5. https://doi.org/10.1016/j.ophtha.2006.07.047
9.Wang DY, Zhao XY, Zhang WF. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. Sci Rep. 2020 Nov 3;10(1):18880. https://doi.org/10.1038/s41598-020-75896-8
10.Pasyechnikova NV, Naumenko VO, Korol AR, Zadorozhnyy OS, Kustryn TB, Henrich PB. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study. Ophthalmologica. 2015;233(1):2-7. https://doi.org/10.1159/000369397
11.Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. Jul-Aug 2006;26(6):699-700.
https://doi.org/10.1097/01.iae.0000225351.87205.69
12.Yeoh J, Williams C, Allen P. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Exp Ophthalmol. 2008 Jul;36(5):449-54. https://doi.org/10.1111/j.1442-9071.2008.01805.x
13.Rizzo S, Genovesi-Ebert F, Di Bartolo E. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008 Jun;246(6):837-42. https://doi.org/10.1007/s00417-008-0774-y
14.El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2008 Dec;2(4):709-16. https://doi.org/10.2147/OPTH.S3521
15.Ahmadieh H, Shoeibi N, Entezari M. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009 Oct;116(10):1943-8. https://doi.org/10.1016/j.ophtha.2009.07.001
16.Yeh PT, Yang CM, Lin YC. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009 Jun;29(6):768-74. https://doi.org/10.1097/IAE.0b013e3181a3b7ef
17.Ponomarchuk Vira S, Umanets MM, Velychko LM. [Vitreous VEGF levels and features of vitrectomy after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy]. In: [Proceedings of the National Conference on Current Issues of Ophthalmology]. September 22-23, 2021. Mykolaiv, Ukraine. Ukrainian.
18.Ponomarchuk Vira S, Velychko LM, Umanets MM. Vitreous VEGF levels among patients with proliferative diabetic retinopathy depending on the general clinical status and ocular status. J Ophthalmol (Ukraine). 2021;4: 19-25. https://doi.org/10.31288/oftalmolzh202141925
19.Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4. https://doi.org/10.1053/sonc.2002.37264
20.Korol A, Kustryn T, Zadorozhnyy O. Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up. J Ocul Pharmacol Ther. 2020 Mar;36(2):122-125. https://doi.org/10.1089/jop.2019.0080
21.Gupta A, Bansal R, Gupta V. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. Int Ophthalmol. 2012 Apr;32(2):135-44. https://doi.org/10.1007/s10792-012-9541-5
22.Hu L, Chen Q, Du Z. Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy. Int Ophthalmol. 2021 May;41(5):1635-1642. https://doi.org/10.1007/s10792-021-01703-6
23.Lo WR, Kim SJ, Aaberg TM Sr. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. Jul-Aug 2009;29(7):926-31. https://doi.org/10.1097/IAE.0b013e3181a8eb88
24.Velazquez JC, Aleman I, Rush SW. Bevacizumab before Diabetic Vitrectomy: A Clinical Trial Assessing 3 Dosing Amounts. Ophthalmol Retina. 2018 Oct;2(10):1010-1020. https://doi.org/10.1016/j.oret.2018.04.014
25.Zhao LQ, Zhu H, Zhao PQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011 Sep;95(9):1216-22. https://doi.org/10.1136/bjo.2010.189514
26.Ruban AM. [Risk factors for neovascular glaucoma after miniinvasive vitrectomy for proliferative diabetic retinopathy]. Medychna informatika ta inzheneriia. 2014;3:51-6. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Віра С. Пономарчук , А. Р. Король , М. М. Уманець
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
